WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 564421
CAS#: 113617-63-3
Description: Orbifloxacin is an antibiotic which is effective against most Gram-negative bacteria, including Enterobacteriaceae and Pseudomonas.
MedKoo Cat#: 564421
Name: Orbifloxacin
CAS#: 113617-63-3
Chemical Formula: C19H20F3N3O3
Exact Mass: 395.1457
Molecular Weight: 395.38
Elemental Analysis: C, 57.72; H, 5.10; F, 14.42; N, 10.63; O, 12.14
Synonym: Orbax; Orbifloxacin
IUPAC/Chemical Name: 1-Cyclopropyl-7-[(3S,5R)-3,5-dimethylpiperazin-1-yl]-5,6,8-trifluoro-4-oxoquinoline-3-carboxylic acid
InChi Key: QIPQASLPWJVQMH-DTORHVGOSA-N
InChi Code: InChI=1S/C19H20F3N3O3/c1-8-5-24(6-9(2)23-8)17-14(21)13(20)12-16(15(17)22)25(10-3-4-10)7-11(18(12)26)19(27)28/h7-10,23H,3-6H2,1-2H3,(H,27,28)/t8-,9+
SMILES Code: O=C(C1=CN(C2CC2)C3=C(C(F)=C(F)C(N4C[C@H](C)N[C@H](C)C4)=C3F)C1=O)O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.03.00
The following data is based on the product molecular weight 395.38 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Shimizu T, Harada K, Manabe S, Tsukamoto T, Ito N, Hikasa Y. Assessment of urinary pharmacokinetics and pharmacodynamics of orbifloxacin in healthy dogs with ex vivo modelling. J Med Microbiol. 2017 May;66(5):616-621. doi: 10.1099/jmm.0.000476. Epub 2017 May 4. PubMed PMID: 28470147.
2: Shimizu T, Harada K. Determination of minimum biofilm eradication concentrations of orbifloxacin for canine bacterial uropathogens over different treatment periods. Microbiol Immunol. 2017 Jan;61(1):17-22. doi: 10.1111/1348-0421.12461. PubMed PMID: 28042660.
3: Santos OM, Freitas JT, Cazedey EC, de Araújo MB, Doriguetto AC. Structure, Solubility and Stability of Orbifloxacin Crystal Forms: Hemihydrate versus Anhydrate. Molecules. 2016 Mar 9;21(3):328. doi: 10.3390/molecules21030328. PubMed PMID: 27005603.
4: Watson MK, Wittenburg LA, Bui CT, Jarosz KA, Gustafson DL, Johnston MS. Pharmacokinetics and bioavailability of orbifloxacin oral suspension in New Zealand White rabbits (Oryctolagus cuniculus). Am J Vet Res. 2015 Nov;76(11):946-51. doi: 10.2460/ajvr.76.11.946. PubMed PMID: 26512539.
5: Harada K, Sasaki A, Shimizu T. Effects of oral orbifloxacin on fecal coliforms in healthy cats: a pilot study. J Vet Med Sci. 2016 Jan;78(1):83-9. doi: 10.1292/jvms.15-0407. Epub 2015 Aug 27. PubMed PMID: 26311787; PubMed Central PMCID: PMC4751121.
6: Dudhatra GB, Kumar A, Awale MM, Kamani DR, Chauhan BN, Patel HB, Mody SK. Determination of orbifloxacin in sheep plasma by high performance liquid chromatography with ultraviolet detection after intravenous and intramuscular administration. J Pharmacol Toxicol Methods. 2013 Jan-Feb;67(1):50-3. doi: 10.1016/j.vascn.2012.11.002. Epub 2012 Dec 8. PubMed PMID: 23231925.
7: Harada K, Shimizu T, Kataoka Y, Takahashi T. Post-antibiotic effect of orbifloxacin against Escherichia coli and Pseudomonas aeruginosa isolates from dogs. Acta Vet Scand. 2012 Mar 20;54:16. doi: 10.1186/1751-0147-54-16. PubMed PMID: 22433170; PubMed Central PMCID: PMC3338406.
8: Tohamy MA. Comparative pharmacokinetics of orbifloxacin in healthy and Pasteurella multocida infected ducks. Br Poult Sci. 2011 Oct;52(5):639-44. doi: 10.1080/00071668.2011.616953. PubMed PMID: 22029792.
9: Marín P, Fernández-Varón E, Escudero E, Vancraeynest D, Cárceles CM. Pharmacokinetic-pharmacodynamic integration of orbifloxacin in rabbits after intravenous, subcutaneous and intramuscular administration. J Vet Pharmacol Ther. 2008 Feb;31(1):77-82. doi: 10.1111/j.1365-2885.2007.00927.x. PubMed PMID: 18177323.
10: Haines GR, Brown MP, Gronwall RR, Merritt KA, Baltzley LK. Pharmacokinetics of orbifloxacin and its concentration in body fluids and in endometrial tissues of mares. Can J Vet Res. 2001 Jul;65(3):181-7. PubMed PMID: 11480524; PubMed Central PMCID: PMC1189673.
